The two recent prospective randomized trials CARMENA and SURTIME have changed the
therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to …

Systemic therapy for patients with metastatic renal cell carcinoma (mRCC) is rapidly
evolving, influencing the optimal integration of cytoreductive nephrectomy (CN) into …

Purpose: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma
(mRCC) was challenged by the results of the CARMENA trial. Here we evaluate the role of …

In the past decades, several treatments have been proposed for the management of
metastatic renal cell carcinoma (mRCC). Among these, cytoreductive nephrectomy (CN) …

Background Currently, the progress of targeted drugs in the treatment of metastatic clear cell
renal cell carcinoma (mccRCC) is limited. Cytoreductive nephrectomy (CN), as an …

Purposes To examine the factors related to the choice of cytoreductive nephrectomy (CN) for
patients with metastatic clear cell renal cell carcinoma (mCCRCC), and compare the …

Introduction Utility of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma
(mRCC) has been questioned utilizing data from patients treated with tyrosine kinase …

In the past two decades, therapy development in the treatment of renal cell carcinoma has
exploded. In our Special Issue on cancers,“Therapy Development in Renal Cell Carcinoma” …

Learning Objectives Summarize the relationship of data on nephrectomy in metastatic RCC
to immunotherapy. Apply to your practice available prognostic predictive scoring systems …

416 Background: Immunotherapy-based systemic treatment (ST) is the standard of care for
most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive …